These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24791651)

  • 1. Why and how should we measure disease activity and damage in lupus?
    Feld J; Isenberg D
    Presse Med; 2014 Jun; 43(6 Pt 2):e151-6. PubMed ID: 24791651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.
    Griffiths B; Mosca M; Gordon C
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):685-708. PubMed ID: 16150398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM; Marx AS; Barry NN
    J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
    Jolly M; Annapureddy N; Arnaud L; Devilliers H
    Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the assessment of lupus disease activity and damage.
    Rao V; Gordon C
    Curr Opin Rheumatol; 2014 Sep; 26(5):510-9. PubMed ID: 25010438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI).
    Lattanzi B; Consolaro A; Solari N; Ruperto N; Martini A; Ravelli A
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S112-7. PubMed ID: 22588739
    [No Abstract]   [Full Text] [Related]  

  • 11. The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.
    Devilliers H; Bonithon-Kopp C; Jolly M
    Lupus; 2017 Apr; 26(4):396-402. PubMed ID: 27587460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of menopause on disease activity in systemic lupus erythematosus.
    Urowitz MB; Ibañez D; Jerome D; Gladman DD
    J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000.
    Yee CS; Isenberg DA; Prabu A; Sokoll K; Teh LS; Rahman A; Bruce IN; Griffiths B; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Zoma A; Gordon C
    Ann Rheum Dis; 2008 Jun; 67(6):873-6. PubMed ID: 17519277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
    Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
    J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A; Chakravarty E; James JA; Merrill JT
    Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.
    Mina R; Abulaban K; Klein-Gitelman MS; Eberhard BA; Ardoin SP; Singer N; Onel K; Tucker L; O'neil K; Wright T; Brooks E; Rouster-Stevens K; Jung L; Imundo L; Rovin B; Witte D; Ying J; Brunner HI
    Arthritis Care Res (Hoboken); 2016 Feb; 68(2):195-202. PubMed ID: 26213987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.
    Isenberg DA; Allen E; Farewell V; D'Cruz D; Alarcón GS; Aranow C; Bruce IN; Dooley MA; Fortin PR; Ginzler EM; Gladman DD; Hanly JG; Inanc M; Kalunian K; Khamashta M; Merrill JT; Nived O; Petri M; Ramsey-Goldman R; Sturfelt G; Urowitz M; Wallace DJ; Gordon C; Rahman A
    Ann Rheum Dis; 2011 Jan; 70(1):54-9. PubMed ID: 20833737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between health-related quality of life and SLE activity and damage in children over time.
    Moorthy LN; Peterson MG; Hassett AL; Baratelli M; Chalom EC; Hashkes PJ; Hong S; Reiff A; Lehman TJ
    Lupus; 2009 Jun; 18(7):622-9. PubMed ID: 19433463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.
    Gladman DD; Goldsmith CH; Urowitz MB; Bacon P; Bombardier C; Isenberg D; Kalunian K; Liang MH; Maddison P; Nived O
    J Rheumatol; 1994 Aug; 21(8):1468-71. PubMed ID: 7983648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
    Sato JO; Corrente JE; Saad-Magalhães C
    Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.